Results 211 to 220 of about 384,012 (260)

Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B.

Journal of the American College of Cardiology
BACKGROUND Patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) have high mortality and morbidity. Vutrisiran, a subcutaneous RNA interference therapeutic, reduced the composite of all-cause mortality (ACM) and cardiovascular (CV) events
R. Witteles, P. García-Pavía, Thibaud Damy, M. Grogan, Farooq H. Sheikh, C. Morbach, S. Bender, Jason Exter, S. Eraly, Marianna Fontana   +9 more
semanticscholar   +1 more source

Scintigraphic Characterization of Amyloid Cardiomyopathy

Clinical Nuclear Medicine, 1985
Amyloidosis is an important entity in the differential diagnosis of cardiac failure of undetermined etiology. In this case report, the typical pattern of combined systolic and diastolic impairment in amyloid cardiomyopathy was demonstrated by analysis of the cardiac blood pool study.
C K, Li, M A, Rabinovitch, J E, Juni, J H, Thrall, B, Pitt, S K, Das, G D, Abrams, M, Helvie   +7 more
openaire   +2 more sources

Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy.

JACC. Heart failure
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative cardiomyopathy that results from myocardial deposition of misfolded transthyretin (TTR) protein.
Jan M. Griffin, J. Grodin, Fredrick Ruberg, Ahmad Masri, Mazen Hanna, Mathew S. Maurer   +5 more
semanticscholar   +1 more source

Tafamidis for Transthyretin Amyloid Cardiomyopathy

New England Journal of Medicine, 2019
Abstract not ...
Maurer, Mathew S, Sultan, Marla B, Rapezzi, Claudio   +2 more
openaire   +4 more sources

SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy.

Journal of the American College of Cardiology
BACKGROUND Transthyretin cardiomyopathy (ATTR-CM) was an exclusion criterion in randomized clinical trials of sodium-glucose cotransporter 2 inhibitors (SGLT2i).
A. Porcari, F. Cappelli, C. Nitsche, D. Tomasoni, G. Sinigiani, S. Longhi, Luca Bordignon, Ahmad Masri, Matteo Serenelli, M. Urey, B. Musumeci, A. Cipriani, Marco Canepa, R. Badr-Eslam, C. Kronberger, Cristina Chimenti, M. Zampieri, Valentina Allegro, Y. Razvi, R. Patel, A. Ioannou, M. Rauf, A. Petrie, C. Whelan, M. Emdin, M. Metra, Marco Merlo, G. Sinagra, P. Hawkins, S. Solomon, J. Gillmore, M. Fontana   +31 more
semanticscholar   +1 more source

Aging, Amyloid, and Cardiomyopathy

New England Journal of Medicine, 1997
In past decades, rheumatic heart disease, syphilitic heart disease, hypertensive heart disease, and even nutritional deficiencies were common enough for physicians to consider these diagnoses in pa...
openaire   +2 more sources

Cardiac disease monitoring measures in patients with transthyretin amyloid cardiomyopathy treated with tafamidis

Heart
Background Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) often experience worsening cardiac disease (WCD) despite disease-modifying treatment. However, a strict definition is lacking.
Dimitrios Bampatsias, Abdirahman Wardhere, Lawrence Zeldin, Alfonsina Mirabal-Santos, Ariel Y Weinsaft, Juliana C Levy, Dia A. Smiley, Sergio Teruya, M. Maurer   +8 more
semanticscholar   +1 more source

Pharmacological Management of Transthyretin Amyloid Cardiomyopathy: Where We Are and Where We Are Going

Journal of Clinical Medicine
Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a progressive disease that has emerged as a significant cause of heart failure. Advances in the understanding of ATTR-CM pathophysiology have revolutionised its therapeutic landscape over the past ...
L. De Michieli, Alessandro Lupi, G. Sinigiani, Angela Tietto, A. Salvalaggio, A. Branca, Stefano Da Pozzo, Stefania Rizzo, D. Cecchin, M. Perazzolo Marra, Tamara Berno, Domenico Corrado, C. Briani, A. Cipriani   +13 more
semanticscholar   +1 more source

Transthyretin amyloid cardiomyopathy: Evolving therapies, expanding hope.

Progress in cardiovascular diseases
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and life-threatening condition characterized by the deposition of misfolded transthyretin (TTR) protein in the myocardium, leading to restrictive cardiomyopathy and heart failure.
J. Costabel, Leonardo Lucas Suarez, Yogita Rochlani, Ahmad Masri, Leandro Slipczuk, E. Berrios   +5 more
semanticscholar   +1 more source

Advances in the screening, diagnosis, and treatment of transthyretin amyloid cardiomyopathy: New insights and future directions.

Trends in cardiovascular medicine
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive form of heart failure caused by myocardial tissue infiltration with fibrillar amyloid deposits.
Andrew A. Girard, Talal Asif, Brett W. Sperry   +2 more
semanticscholar   +1 more source